VL285

CAS No. 1448188-57-5

VL285( —— )

Catalog No. M20084 CAS No. 1448188-57-5

VL285 is a potent VHL ligand degrading HaloTag7 fusion proteins.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 107 In Stock
5MG 92 In Stock
10MG 147 In Stock
25MG 297 In Stock
50MG 439 In Stock
100MG 617 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    VL285
  • Note
    Research use only, not for human use.
  • Brief Description
    VL285 is a potent VHL ligand degrading HaloTag7 fusion proteins.
  • Description
    VL285 is a potent VHL ligand degrading HaloTag7 fusion proteins.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PROTACs
  • Target
    E3 Ligase Ligand
  • Recptor
    VHL
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1448188-57-5
  • Formula Weight
    532.65
  • Molecular Formula
    C29H32N4O4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 53.26 mg/mL (100 mM)
  • SMILES
    CC(C)[C@H](N1Cc2ccccc2C1=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(cc1)-c1scnc1C
  • Chemical Name
    (2S4R)-4-Hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Buckley DL et al. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. ACS Chem Biol. 2015 Aug 21;10(8):1831-7.
molnova catalog
related products
  • E3 Ligand-Linker Con...

    An E3 ligase ligand-linker conjugate for PROTAC.

  • Pomalidomide-C2-NH2 ...

    Pomalidomide-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

  • Golcadomide

    Golcadomide (CC-99282) is a orally active CRBN E3 ligase modulator that induces interactions between CRBN and its neo-substrate, recruiting the target disease-causing proteins and the E3 ubiquitin ligase.